APTAR PHARMA IS CONFERENCE PARTNER FOR THE 5th SYMPOSIUM ON NASAL AND PULMONARY DRUG DELIVERY

Aptar Pharma, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, is conference partner for the Indian Pharmaceutical Association's fifth symposium on “Nasal and Pulmonary Drug Delivery” with the theme of “Regulatory Challenges: The Way Forward”. This symposium will be held in Mumbai, India, on November 10th and 11th, 2011.


A major biennial meeting in India for sharing knowledge about Orally Inhaled and Nasal Drug Products (OINDP)

This two-day scientific symposium tailored specifically to nasal and pulmonary drug delivery will welcome an audience of more than 160 participants from Europe, India and the USA.

A panel of 13 highly renowned scientists and technical experts will debate regulatory challenges related to nasal and pulmonary drug delivery systems. Symposium lectures and facilitated workshops will include:

• Dr Richard Dalby, University of Maryland School of Pharmacy (USA): “Bioequivalence for OINDP: progress and remaining hurdles identified by 40 experts with 1,000 years of combined aerosol experience” and “New approaches to nasal spray evaluation. Pediatric versus adult actuation profiles and anatomically based spray pattern tests”

• Dr Tim Noakes, Mexichem Fluor (UK): “Medical propellants: now and in future. Using them and how things may change”

• Dr Julie Suman, Next Breath LLC (USA): “Recent developments in establishing in-vitro and in-vivo correlations”

• Dr Sameer Updaeo, Malvern Instruments Ltd (India): “Characterization of pharmaceutical aerosols using Malvern Spraytec”

• Dr Gerallt Williams, Aptar Pharma (France): “Comparative analysis of in-use actuation parameters with in-vitro performance of nasal spray pumps”

• Mr Mark Copley, Copley Scientific (UK): “Advances in cascade impaction for the in-vitro APSD measurement of OINDP”

• Dr Paul Kippax, Malvern Instruments Ltd (UK): “Characterizing nasal spray formulations from droplet to API particle size”

• Mr Henrik Krarup, Innova Systems (USA): “New advances in automated actuations of drug delivery products” and “Spray pattern and plume geometry. How to follow the guidances by the FDA”

• Mr Hervé Pacaud and Mr Chris Baron, Aptar Pharma (France): “Metering valves for HFAs: factors to consider, challenges and emerging trends”

• Mr Paul Sullivan, DH Industries Ltd (UK): “pMDI aerosol filling equipment. Requirements for regulatory production”

• Mr Richard Turner, Presspart (UK): “HFA challenges related to canister specification and plasma technology”

• Mr Andrew Wood, Aptar Pharma (France): “New directives and guides from the regulators of container-closure systems”


A significant investment in India

Established since 1999 in Mumbai, Aptar Pharma is the market leader in India. We provide innovative and proven aerosol, spray and dispensing systems to biotechnology, healthcare and pharmaceutical companies in India.

Aptar Pharma India will be setting up a production facility close to Mumbai in the near future. This facility, which will be the first of its kind in India, will be key in furthering our commitment to provide world class quality products locally to our customers.

Aptar Pharma is a recognized market leader in Asia, including India, and continues to expand its activity, leveraging an in-depth network of local partners to forge strong links with a wide range of local players, including those in research, industry, academia and regulatory bodies.

“Aptar Pharma is very pleased to continue this long standing collaboration with the Indian Pharmaceutical Association to offer a high quality symposium on nasal and pulmonary drug delivery”, said Marc Prieur, President Aptar Pharma Asia. “This is now a well-established event, and this year the fifth edition of the symposium will have a record attendance of over 160 delegates.”